Related Experiment Video
Updated: Jun 2, 2026

Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors
Published on: October 20, 2023
p53 inhibits adeno-associated viral vector integration
Jeana Zacharias1, Liudmila G Romanova, Jeremiah Menk
1Division of Rheumatic and Autoimmune Diseases, Department of Medicine, Institute of Human Genetics, University of Minnesota, Minneapolis, MN 55455, USA.
Abstract:
Adeno-associated viral (AAV) vectors preferentially integrate into the genome of cells that are defective in DNA repair, such as occurs with DNA-PKcs deficiency or poly(ADP-ribose) polymerase-1 down-regulation. As the tumor suppressor protein p53 regulates the transcription of many genes involved in DNA repair, we sought to determine whether functional p53 affects the efficiency of AAV integration. p53 is mutated in more than 50% of cancers, and site-specific integration of AAV into the AAVS1 site of human chromosome 19 has frequently been observed in transformed cancer cell lines, but rarely seen in primary cells or in vivo. We therefore hypothesized that p53-negative cells would be more permissive to AAV integration than p53-positive cells. The integration of a rep- and green fluorescent protein-encoding recombinant AAV vector was quantified in p53-expressing and p53-deficient HCT116 colon cancer cells. Our results show that there is a higher efficiency of AAV integration in p53-negative cells compared with p53-positive cells, indicating that p53 does indeed inhibit AAV integration. Further experiments suggest that this p53-mediated block to AAV integration is likely to be through binding of p53 to the AAV Rep protein and the consequent inhibition of Rep activity during AAV integration.
Insights
Functional p53 protein inhibits adeno-associated viral (AAV) vector integration into the genome. P53-deficient cells show higher AAV integration efficiency, suggesting p53
Area of Science:
- Molecular Biology
- Genetics
- Virology
Background:
- Adeno-associated viral (AAV) vectors are utilized in gene therapy, with integration efficiency influenced by cellular DNA repair pathways.
- AAV vectors preferentially integrate into DNA repair-deficient cells, such as those with DNA-PKcs deficiency or reduced poly(ADP-ribose) polymerase-1.
- The tumor suppressor protein p53 plays a critical role in regulating DNA repair gene transcription, and its mutation is common in cancers.
Purpose of the Study:
- To investigate the effect of functional p53 on the efficiency of adeno-associated viral (AAV) vector integration.
- To test the hypothesis that p53-negative cells are more permissive to AAV integration than p53-positive cells.
Main Methods:
- Quantification of recombinant AAV vector integration (encoding rep and green fluorescent protein) in HCT116 colon cancer cells.
- Comparison of AAV integration efficiency between p53-expressing (p53-positive) and p53-deficient (p53-negative) cell lines.
Main Results:
- A significantly higher efficiency of AAV integration was observed in p53-negative cells compared to p53-positive cells.
- These findings indicate that functional p53 actively inhibits AAV integration.
- Further experiments suggest p53 binds to the AAV Rep protein, inhibiting its activity during integration.
Conclusions:
- Functional p53 acts as a barrier to adeno-associated viral (AAV) vector genome integration.
- The p53-mediated inhibition of AAV integration is likely due to direct interaction with the AAV Rep protein.
- Understanding this interaction could inform strategies for enhancing AAV vector integration in gene therapy applications.
More Related Videos
04:29Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA
Published on: November 1, 2024
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019
Related Concept Videos
Abnormal Proliferation
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis